Sun Pharma's reported $12-billion bid for Organon & Co., if completed, would be among the largest overseas acquisitions by an Indian pharmaceutical company, bringing a global women’s health portfolio and US commercial operations.

Sun Pharma has described reports of the transaction as “speculative” in an exchange filing on Friday, stating that no material event requiring disclosure under Regulation 30 had occurred. However, people familiar with the matter indicate that the company has completed due diligence over the past few months and is working on financing arrangements, with global lenders said to be involved. The proposed transaction, estimated at around $12 billion, marks a step-up from an earlier non-binding offer of about $10 billion.

Unlike the 2014 acquisition of Ranbaxy Laboratories, which involved turning around a distressed domestic asset, the proposed Organon deal involves a scaled global business with an established commercial footprint and diversified portfolio.

“We would look at acquisition only if we think that it can help us in terms of strengthening our long-term strategy capability,” chairman Dilip Shanghvi said during the company’s Q3 FY26 earnings call.

He added that the company remains disciplined about acquisitions and aims to ensure that any transaction can be managed without diluting focus on its existing business. He also indicated that the US continues to remain an important focus market, particularly for innovative medicines, alongside efforts to expand globally.

Sun Pharma has further indicated comfort with raising debt for acquisitions, subject to maintaining balance in its overall business. Market reaction to the reported deal has been immediate. Shares of Sun Pharma declined over 3% in Mumbai, while Organon rose more than 20% across two trading sessions in New York.

The scale of the proposed transaction would make it one of the largest overseas acquisitions by an Indian pharmaceutical company. It would also add a global portfolio with multiple therapy segments, requiring integration across markets and product lines.

Pharma analysts say the nature of the asset differs from the company’s earlier acquisitions. “This is not a turnaround opportunity. Value will need to be built over time through execution and portfolio management,” said Salil Kallianpur. “When you pay more upfront, you are reducing the margin for execution,” he added.

Organon & Co., which was spun off from Merck & Co. in 2021, operates across women’s health, biosimilars and established brands, with a presence in multiple international markets.

For Sun Pharma, the acquisition would provide access to global front-end operations, particularly in the US, along with a portfolio of branded products, complementing its existing presence in specialty and generics.

A key part of Organon’s portfolio is women’s health, covering contraception, fertility and lifecycle therapies. The company has recently expanded its contraception portfolio through licensing agreements and secured approvals to extend the duration of its contraceptive implant, Nexplanon.

At the same time, Organon’s recent disclosures point to a stable but evolving business. The company reported revenue of $6.2 billion in 2025, down 3% year-on-year, and posted a net loss of $205 million in the fourth quarter, including a goodwill impairment linked to underperformance of certain products in the US. It has guided for largely stable performance in 2026.

The company is also undergoing a leadership transition. Organon said in October 2025 that CEO Kevin Ali stepped down following an Audit Committee review into sales practices related to its Nexplanon product, with Joseph Morrissey appointed interim chief executive.